MEVPRO-1 and MEVPRO-2: Phase III Prostate Cancer Trial Protocols

Two ongoing global Phase III clinical trial protocols for metastatic castration-resistant prostate cancer (mCRPC) are described. MEVPRO-1 targets ~600 patients with prior abiraterone treatment, while MEVPRO-2 targets ~900 treatment-naïve patients. The trials, authored by Neal D. Shore and published on figshare in 2026, compare mevrometostat plus enzalutamide against standard therapies.

Use Cases

• Analyze trial design and patient eligibility criteria based on the described inclusion/exclusion parameters
• Compare treatment arms and dosing regimens based on the described 1:1 randomization to mevrometostat plus enzalutamide versus physician's choice
• Study primary and secondary endpoints for oncology trials based on the described radiographic progression-free survival (rPFS) and overall survival objectives

Strengths

• Protocols are for large-scale Phase III trials with planned enrollments of ~600 and ~900 patients
• Includes specific clinical trial registration identifiers (NCT06551324, NCT06629779) for verification
• Describes detailed patient criteria, including ECOG performance status and prior treatment history

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is a small 84.2 KB document, containing only the trial protocols without patient-level data

Provenance

Source

figshare

Collection Method

Published trial protocol document

Freshness

Last updated 2026-05-11 05:19:46; freshness should be verified

Geography

Global trial sites